MeiraGTx Holdings (MGTX) EBT Margin (2019 - 2026)
MeiraGTx Holdings' (MGTX) quarterly EBT Margin came in at 19.37% in Q4 2025, up 17455.0% YoY from N/an in Q4 2024, and up 100.16% on a QoQ basis from 11940.24% in Q3 2025.
Powered by 
Analysis
MeiraGTx Holdings (MGTX) EBT Margin (2019 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 7 years of EBT Margin data on file, last reported at 19.37% in Q4 2025.
- Quarterly EBT Margin rose 17455.0% year-over-year to 19.37% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 122.36% (up 40249.0% YoY) and the FY2025 annual result came in at 352.85%, up 57701.0% from the prior year.
- EBT Margin climbed to 19.37% in Q4 2025, from 11940.24% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 793.55% in Q4 2022 to a low of 18101.77% in Q2 2024.
- A 5-year average of 2251.56% and a median of 503.35% in 2021 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin sank 1721237 bps — and 2025, when it jumped 1697956 bps.
- Tracing MGTX's EBT Margin over 5 years: stood at 37.0% in 2021, then soared by 2245 bps to 793.55% in 2022, then slumped by 59 bps to 322.11% in 2023, then plunged by 148 bps to 155.18% in 2024, then jumped by 112 bps to 19.37% in 2025.
- The last three EBT Margin figures came in at 19.37% (Q4 2025), 11940.24% (Q3 2025), and 1122.22% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 75.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.17% |
| Dec 31, 2025 | 20.52% |
| Sep 30, 2025 | -13,028.54% |
| Jun 30, 2025 | -1,284.72% |
| Mar 31, 2025 | -2,267.29% |
| Dec 31, 2024 | -158.34% |
| Sep 30, 2024 | -386.88% |
| Jun 30, 2024 | -18,101.77% |
| Mar 31, 2024 | -7,019.37% |
| Dec 31, 2023 | -2,286.96% |
| Sep 30, 2023 | -698.02% |
| Jun 30, 2023 | -889.41% |
| Mar 31, 2023 | -1,028.04% |
| Dec 31, 2022 | 822.96% |
| Sep 30, 2022 | -506.89% |
| Jun 30, 2022 | -221.20% |
| Mar 31, 2022 | -511.18% |
| Dec 31, 2021 | -37.00% |
| Sep 30, 2021 | -324.96% |
| Jun 30, 2021 | -400.06% |